ReviewCureus2025
Beyond the Bone Health: A Narrative Review Unveiling the Role of Bisphosphonates in Reducing the Risk of Myocardial Infarction.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates, a class of anti-osteoporotic drugs, are known to inhibit bone resorption and reduce fracture risk. This review evaluates the evidence for their use and also aims to assess their potential benefits, safety, and effectiveness in reducing the risk of myocardial infarction. Bisphosphonates, in addition to their conventional role in bone health, reduce the accumulation of calcium within vascular walls. Therefore, they are known to decrease the potential risk of myocardial infarction in patients with a higher likelihood of cardiovascular problems. However, they may exacerbate other cardiac issues and do not appear to reduce mortality rates. Bisphosphonates, when used as an anti-osteoporotic drug, generally have a favorable safety profile in patients with osteoporosis, regardless of treatment duration, age, sex, or underlying cardiovascular conditions. Nonetheless, strict adherence to bisphosphonate therapy over a longer duration may help reduce the risk of myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.